Metsera, an obesity drug developer, said on Friday that it has entered into an amended merger agreement with Pfizer, in which the New York-based company will acquire Metsera for up to $86.25 per share.
Metsera's board has recommended that its shareholders "approve the adoption of the amended Pfizer merger agreement and approve the merger with Pfizer."
https://www.streetinsider.com/Reuters/Metsera+enters+merger+agreement+with+Pfizer/25579753.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.